Abstract
The standard curative treatment is radical prostatectomy (RP) or radiation therapy (RT) in localized prostate cancer (Pca). Unfortunately, at most 30% of the patients develop biochemical recurrent that can be identified by rising prostate-specific antigen (PSA) only but not detectable by CT scan or bone scan. The new technology like chorine PET and ProstaScint could detect the recurrent site, but these modalities are insufficient in low PSA level (less than 1.0 ng/mL) of PSA failure patients after definitive therapy. Many of those patients with biochemical recurrence after RP would initially be treated by salvage RT. But, in patients with biochemical recurrence after RT, salvage RP is performed in only selective patients and most of them are treated by salvage hormone therapy (HT). There are conflicting evidences to support the advantage of salvage ADT; one randomized controlled trial (RCT) showed the benefit of early starting of HT, and another RCT proved the non-inferiority of intermittent ADT to continuous ADT. In this chapter, recent evidences are summarized on salvage ADT after definitive treatment for clinically localized Pca.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Carroll P. Rising PSA after a radical treatment. Eur Urol. 2001;40(Suppl 2):9–16. https://doi.org/10.1159/000049879.
Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):418–30. https://doi.org/10.1016/j.eururo.2012.05.046.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29. https://doi.org/10.1016/j.eururo.2016.08.003.
Freedland SJ, Rumble RB, Finelli A, Chen RC, Slovin S, Stein MN, et al. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2014;32(34):3892–8. https://doi.org/10.1200/jco.2014.58.8525.
NCCN guideline, prostate cancer 2017v2. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Shioyama Y, Tsuji H, Suefuji H, Sinoto M, Matsunobu A, Toyama S, et al. Particle radiotherapy for prostate cancer. Int J Urol. 2015;22(1):33–9. https://doi.org/10.1111/iju.12640.
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74. https://doi.org/10.1016/j.ijrobp.2006.04.029.
Yokomizo A, Kawamoto H, Nihei K, Ishizuka N, Kakehi Y, Tobisu K, et al. Randomized controlled trial to evaluate radiotherapy +/− endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol. 2005;35(1):34–6. https://doi.org/10.1093/jjco/hyi007.
Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, et al. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int. 2006;98(3):549–53. https://doi.org/10.1111/j.1464-410X.2006.06379.x.
Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160(4):1387–91.
Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64(1):106–17. https://doi.org/10.1016/j.eururo.2013.04.019.
Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol. 2013;31(4):427–35. https://doi.org/10.1016/j.urolonc.2010.08.008.
Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, et al. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncol (London, England). 2014;10(3):457–74. https://doi.org/10.2217/fon.13.196.
Koontz BF, Mouraviev V, Johnson JL, Mayes J, Chen SH, Wong TZ, et al. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):358–61. https://doi.org/10.1016/j.ijrobp.2007.10.020.
Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med. 1998;23(10):672–7.
Souhami L, Bae K, Pilepich M, Sandler H. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31. Int J Radiat Oncol Biol Phys. 2010;78(5):1301–6. https://doi.org/10.1016/j.ijrobp.2009.10.007.
Mydin AR, Dunne MT, Finn MA, Armstrong JG. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy—a secondary analysis of Irish clinical oncology research group 97-01. Int J Radiat Oncol Biol Phys. 2013;85(1):101–8. https://doi.org/10.1016/j.ijrobp.2012.03.001.
Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17(6):727–37. https://doi.org/10.1016/s1470-2045(16)00107-8.
Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol. 2008;179(5):1830–7.; discussion 7. https://doi.org/10.1016/j.juro.2008.01.022.
Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59(6):893–9. https://doi.org/10.1016/j.eururo.2011.02.026.
Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367(10):895–903. https://doi.org/10.1056/NEJMoa1201546.
Yokomizo A, Satoh T, Hashine K, Inoue T, Fujimoto K, Egawa S, et al. Randomized controlled trial comparing radiotherapy +/− endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG0401. Ann Oncol. 2017;28(Suppl 5):v269–94. https://doi.org/10.1093/annonc/mdx370.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Yokomizo, A. (2018). ADT as Salvage Therapy After Definitive Treatment for Clinically Localized Prostate Cancer. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_13
Download citation
DOI: https://doi.org/10.1007/978-981-10-7013-6_13
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-7012-9
Online ISBN: 978-981-10-7013-6
eBook Packages: MedicineMedicine (R0)